# US 2008/0306018 A1 · Micro-Rna Expression Abnormalities of Pancreatic, Endocrine and Acinar Tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306018 A1
- Document ID: US20080306018A1
- Status: Published application
- Kind: A1
- Application number: 12/160,064
- Filed: 2007-01-03
- Published: 2008-12-11
- Earliest claimed: 2006-01-05
- Assignees: The Ohio State University
- Inventors: Carlo M. Croce; George A. Calin
- Web page: https://patentgrep.com/patent/US20080306018A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- G01N 33/57525: of the liver or pancreas
- A61N 1/30: Apparatus for iontophoresis, {i.e. transfer of media in ionic state by an electromotoric force into the body}, or cataphoresis
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.

## Claims

### Claim 1

A method of diagnosing whether a subject has, or is at risk for developing, pancreatic cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 3 (depends on 2)

The method of claim 2, wherein the at least one miR gene product is selected from the group consisting of miR-103-2, miR-107, miR-103-1, miR-342, miR-100, miR-24-2, miR-23a, miR-125a, miR-26a-1, miR-24-1, miR-191, miR-15a, miR-368, miR-26b, miR-125b-2, miR-125b-1, miR-26a-2, miR-335, miR-126, miR-1-2, miR-21, miR-25, miR-92-2, miR-130a, miR-93, miR-16-1, miR-145, miR-17, miR-99b, miR-181b-1, miR-146, miR-181b-2, miR-16-2, miR-99a, miR-197, miR-10a, miR-224, miR-92-1, miR-27a, miR-221, miR-320, miR-7-1, miR-29b-2, miR-150, miR-30d, miR-29a, miR-23b, miR-135a-2, miR-223, miR-3p21-v, miR-128b, miR-30b, miR-29b-1, miR-106b, miR-132, miR-214, miR-7-3, miR-29c, miR-367, miR-30c-2, miR-27b, miR-140, miR-10b, miR-20, miR-129-1, miR-340, miR-30a, miR-30c-1, miR-106a, miR-32, miR-95, miR-222, miR-30e, miR-129-2, miR-345, miR-143, miR-182, miR-1-1, miR-133a-1, miR-200c, miR-194-1, miR-210, miR-181c, miR-192, miR-220, miR-213, miR-323, miR-375 and a combination thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein the at least one miR gene product is selected from the group consisting of miR-103, miR-107 and a combination thereof.

### Claim 5 (depends on 2)

The method of claim 2, wherein the at least one miR gene product is selected from the group consisting of miR-23a, miR-26b, miR-192, miR-342 and a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample.

### Claim 7 (depends on 6)

The method of claim 6, wherein the at least one miR gene product is selected from the group consisting of miR-326, miR-155, miR-339, miR-34c, miR-345, miR-152, miR-372, miR-128a and a combination thereof.

### Claim 8 (depends on 6)

The method of claim 6, wherein the at least one miR gene product is miR-155.

### Claim 9 (depends on 1)

The method of claim 1, wherein:
the at least one miR gene product is miR-103, which is upregulated in the test sample, as compared to the control sample;
the at least one miR gene product is miR-107, which is upregulated in the test sample, as compared to the control sample; and/or
the at least one miR gene product is miR-155, which is downregulated in the test sample, as compared to the control sample.

### Claim 10 (depends on 1)

The method of claim 1, wherein said pancreatic cancer is selected from the group consisting of a pancreatic endocrine tumor (PET), a pancreatic acinar cell carcinoma (PACC) and an insulinoma.

### Claim 11

A method of diagnosing whether a subject has, or is at risk for developing, pancreatic acinar cell carcinoma (PACC), comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, PACC.

### Claim 12 (depends on 11)

The method of claim 11, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the at least one miR gene product is selected from the group consisting of miR-103-2, miR-25, miR-200c, miR-335, miR-21, miR-103-1, miR-92-1, miR-181b-2, miR-191, miR-93, miR-26a-1, miR-17, miR-20, miR-107, miR-26b, miR-215, miR-92-2, miR-192, miR-342, miR-100, miR-3p21-v, miR-106a, miR-15a, miR-23a, miR-181b-1, miR-128b, miR-106b, miR-194-1, miR-219-1, miR-242 and a combination thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample.

### Claim 15 (depends on 14)

The method of claim 14, wherein the at least one miR gene product is selected from the group consisting of miR-218-2, miR-339, miR-326, miR-34c, miR-152, miR-138-2, miR-128a and a combination thereof.

### Claim 16

A method of diagnosing the type of pancreatic cancer that a subject has, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the type of pancreatic cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the type of pancreatic cancer is selected from the group consisting of a pancreatic endocrine tumor (PET) and a pancreatic acinar cell carcinoma (PACC).

### Claim 18 (depends on 17)

The method of claim 17, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 19 (depends on 17)

The method of claim 17, wherein the type of pancreatic cancer is a pancreatic endocrine tumor (PET) and the at least one miR gene product is selected from the group consisting of miR-125a, miR-99a, miR-99b, miR-125b-1, miR-342, miR-130a, miR-100, miR-132, miR-129-2, miR-125b-2 and a combination thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample.

### Claim 21 (depends on 20)

The method of claim 20, wherein the type of pancreatic cancer is a pancreatic acinar cell carcinoma (PACC) and the at least one miR gene product is selected from the group consisting of miR-125a, miR-99a, miR-99b, miR-125b-1, miR-342, miR-130a, miR-100, miR-132, miR-129-2, miR-125b-2 and a combination thereof.

### Claim 22 (depends on 16)

The method of claim 16, wherein the type of pancreatic cancer is selected from the group consisting of a well-differentiated endocrine carcinoma (WDEC) and a pancreatic acinar cell carcinoma (PACC).

### Claim 23 (depends on 22)

The method of claim 22, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 24 (depends on 22)

The method of claim 22, wherein the type of pancreatic cancer is a well-differentiated endocrine carcinoma (WDEC) and the at least one miR gene product is selected from the group consisting of miR-125a, miR-99a, miR-132 and a combination thereof.

### Claim 25 (depends on 22)

The method of claim 22, wherein the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample.

### Claim 26 (depends on 25)

The method of claim 25, wherein the type of pancreatic cancer is a well-differentiated endocrine carcinoma (WDEC) and the at least one miR gene product is miR-148a.

### Claim 27 (depends on 16)

The method of claim 16, wherein the type of pancreatic cancer is selected from the group consisting of an insulinoma and a non-functioning pancreatic endocrine tumor (NF-PET).

### Claim 28 (depends on 27)

The method of claim 27, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 29 (depends on 27)

The method of claim 27, wherein the type of pancreatic cancer is an insulinoma and the at least one miR gene product is selected from the group consisting of miR-204, miR-203, miR-211 and a combination thereof.

### Claim 30

A method of determining the prognosis of a subject with pancreatic cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein:
the miR gene product is associated with an adverse prognosis in pancreatic cancer; and
an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of an adverse prognosis.

### Claim 31 (depends on 30)

The method of claim 30, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 32 (depends on 31)

The method of claim 31, wherein the at least one miR gene product is miR-21.

### Claim 33 (depends on 31)

The method of claim 31, wherein the pancreatic cancer is associated with metastasis and/or a high proliferation index.

### Claim 34

A method of determining whether a pancreatic cancer in a subject is metastatic, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein:
the miR gene product is associated with metastasis; and
an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of metastasis.

### Claim 35 (depends on 34)

The method of claim 34, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 36 (depends on 34)

The method of claim 34, wherein the at least one miR gene product is miR-21.

### Claim 37

A method of determining whether a pancreatic cancer in a subject has a high proliferation index, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein:
the miR gene product is associated with a high proliferation index; and
an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of a high proliferation index.

### Claim 38 (depends on 37)

The method of claim 37, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.

### Claim 39 (depends on 37)

The method of claim 37, wherein the at least one miR gene product is miR-21.

### Claim 40

A method of determining the prognosis of a subject with pancreatic cancer, comprising measuring the level of PDCD4 in a test sample from said subject, wherein an alteration in the level of PDCD4 in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of an adverse prognosis.

### Claim 41 (depends on 40)

The method of claim 40, wherein the level of PDCD4 in the test sample is less than the level of PDCD4 in the control sample.

### Claim 42 (depends on 40)

The method of claim 40, wherein the pancreatic cancer is associated with metastasis and/or a high proliferation index.

### Claim 43

A method of diagnosing whether a subject has, or is at risk for developing, pancreatic cancer, comprising:
(1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample; and
(3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
wherein an alteration in the signal of at least one miRNA is indicative of the subject either having, or being at risk for developing, pancreatic cancer.

### Claim 44 (depends on 43)

The method of claim 43 wherein the signal of at least one miRNA, relative to the signal generated from the control sample, is upregulated.

### Claim 45 (depends on 43)

The method of claim 43 wherein the signal of at least one miRNA, relative to the signal generated from the control sample, is down-regulated.

### Claim 46 (depends on 43)

The method of claim 43, wherein the microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR-103-2, miR-107, miR-103-1, miR-342, miR-100, miR-24-2, miR-23a, miR-125a, miR-26a-1, miR-24-1, miR-191, miR-15a, miR-368, miR-26b, miR-125b-2, miR-125b-1, miR-26a-2, miR-335, miR-126, miR-1-2, miR-21, miR-25, miR-92-2, miR-130a, miR-93, miR-16-1, miR-145, miR-17, miR-99b, miR-181b-1, miR-146, miR-181b-2, miR-16-2, miR-99a, miR-197, miR-10a, miR-224, miR-92-1, miR-27a, miR-221, miR-320, miR-7-1, miR-29b-2, miR-150, miR-30d, miR-29a, miR-23b, miR-135a-2, miR-223, miR-3p21-v, miR-128b, miR-30b, miR-29b-1, miR-106b, miR-132, miR-214, miR-7-3, miR-29c, miR-367, miR-30c-2, miR-27b, miR-140, miR-10b, miR-20, miR-129-1, miR-340, miR-30a, miR-30c-1, miR-106a, miR-32, miR-95, miR-222, miR-30e, miR-129-2, miR-345, miR-143, miR-182, miR-1-1, miR-133a-1, miR-200c, miR-194-1, miR-210, miR-181c, miR-192, miR-220, miR-213, miR-323, miR-375, miR-326, miR-155, miR-339, miR-34c, miR-345, miR-152, miR-372, miR-128a and a combination thereof.

### Claim 47

A method of diagnosing whether a subject has, or is at risk for developing, a pancreatic cancer with an adverse prognosis, comprising:
(1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for said test sample; and
(3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
wherein an alteration in the signal is indicative of the subject either having, or being at risk for developing, a pancreatic cancer with an adverse prognosis.

### Claim 48 (depends on 47)

The method of claim 47, wherein an alteration in the signal of miR-21 is indicative of the subject either having, or being at risk for developing, a pancreatic cancer with an adverse prognosis.

### Claim 49

A method of treating pancreatic cancer in a subject who has a pancreatic cancer in which at least one miR gene product is downregulated or upregulated in the cancer cells of the subject relative to control cells, comprising:
(1) when the at least one miR gene product is downregulated in the cancer cells, administering to the subject an effective amount of at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, provided that the miR gene product is not miR-15a or miR-16-1, such that proliferation of cancer cells in the subject is inhibited; or
(2) when the at least one miR gene product is upregulated in the cancer cells, administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, such that proliferation of cancer cells in the subject is inhibited.

### Claim 50 (depends on 49)

The method of claim 49, wherein the at least one isolated miR gene product in step (1) is selected from the group consisting of miR-326, miR-155, miR-339, miR-34c, miR-345, miR-152, miR-372, miR-128a and a combination thereof.

### Claim 51 (depends on 49)

The method of claim 49, wherein the at least one miR gene product in step (2) is selected from the group consisting of miR-103-2, miR-107, miR-103-1, miR-342, miR-100, miR-24-2, miR-23a, miR-125a, miR-26a-1, miR-24-1, miR-191, miR-15a, miR-368, miR-26b, miR-125b-2, miR-125b-1, miR-26a-2, miR-335, miR-126, miR-1-2, miR-21, miR-25, miR-92-2, miR-130a, miR-93, miR-16-1, miR-145, miR-17, miR-99b, miR-181b-1, miR-146, miR-181b-2, miR-16-2, miR-99a, miR-197, miR-10a, miR-224, miR-92-1, miR-27a, miR-221, miR-320, miR-7-1, miR-29b-2, miR-150, miR-30d, miR-29a, miR-23b, miR-135a-2, miR-223, miR-3p21-v, miR-128b, miR-30b, miR-29b-1, miR-106b, miR-132, miR-214, miR-7-3, miR-29c, miR-367, miR-30c-2, miR-27b, miR-140, miR-10b, miR-20, miR-129-1, miR-340, miR-30a, miR-30c-1, miR-106a, miR-3-2, miR-95, miR-222, miR-30e, miR-129-2, miR-345, miR-143, miR-182, miR-1-1, miR-133a-1, miR-200c, miR-194-1, miR-210, miR-181c, miR-192, miR-220, miR-213, miR-323, miR-375 and a combination thereof.

### Claim 52

A method of treating pancreatic cancer in a subject, comprising:
(1) determining the amount of at least one miR gene product in pancreatic cancer cells, relative to control cells; and
(2) altering the amount of miR gene product expressed in the pancreatic cancer cells by:
(i) administering to the subject an effective amount of at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, provided that the miR gene product is not miR-15a or miR-16-1, if the amount of the miR gene product expressed in the cancer cells is less than the amount of the miR gene product expressed in control cells; or
(ii) administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, if the amount of the miR gene product expressed in the cancer cells is greater than the amount of the miR gene product expressed in control cells.

### Claim 53 (depends on 52)

The method of claim 52, wherein the at least one isolated miR gene product in step (i) is selected from the group consisting of miR-326, miR-155, miR-339, miR-34c, miR-345, miR-152, miR-372, miR-128a and a combination thereof.

### Claim 54 (depends on 52)

The method of claim 52, wherein the at least one miR gene product in step (ii) is selected from the group consisting of miR-103-2, miR-107, miR-103-1, miR-342, miR-100, miR-24-2, miR-23a, miR-125a, miR-26a-1, miR-24-1, miR-191, miR-15a, miR-368, miR-26b, miR-125b-2, miR-125b-1, miR-26a-2, miR-335, miR-126, miR-1-2, miR-21, miR-25, miR-92-2, miR-130a, miR-93, miR-16-1, miR-145, miR-17, miR-99b, miR-181b-1, miR-146, miR-181b-2, miR-16-2, miR-99a, miR-197, miR-10a, miR-224, miR-92-1, miR-27a, miR-221, miR-320, miR-7-1, miR-29b-2, miR-150, miR-30d, miR-29a, miR-23b, miR-135a-2, miR-223, miR-3p21-v, miR-128b, miR-30b, miR-29b-1, miR-106b, miR-132, miR-214, miR-7-3, miR-29c, miR-367, miR-30c-2, miR-27b, miR-140, miR-10b, miR-20, miR-129-1, miR-340, miR-30a, miR-30c-1, miR-106a, miR-32, miR-95, miR-222, miR-30e, miR-129-2, miR-345, miR-143, miR-182, miR-1-1, miR-133a-1, miR-200c, miR-194-1, miR-210, miR-181c, miR-192, miR-220, miR-213, miR-323, miR-375 and a combination thereof.

### Claim 55

A pharmaceutical composition for treating pancreatic cancer, comprising at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, and a pharmaceutically-acceptable carrier.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the at least one isolated miR gene product corresponds to a miR gene product that is downregulated in pancreatic cancer cells relative to control cells.

### Claim 57 (depends on 56)

The pharmaceutical composition of claim 56, wherein the isolated miR gene product is selected from the group consisting of miR-326, miR-155, miR-339, miR-34c, miR-345, miR-152, miR-372, miR-128a and a combination thereof.

### Claim 58

A pharmaceutical composition for treating pancreatic cancer, comprising at least one miR expression-inhibitor compound and a pharmaceutically-acceptable carrier.

### Claim 59 (depends on 58)

The pharmaceutical composition of claim 58, wherein the at least one miR expression-inhibitor compound is specific for a miR gene product that is upregulated in pancreatic cancer cells relative to control cells.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the at least one miR expression-inhibitor compound is specific for a miR gene product selected from the group consisting of miR-103-2, miR-107, miR-103-1, miR-342, miR-100, miR-24-2, miR-23a, miR-125a, miR-26a-1, miR-24-1, miR-191, miR-15a, miR-368, miR-26b, miR-125b-2, miR-125b-1, miR-26a-2, miR-335, miR-126, miR-1-2, miR-21, miR-25, miR-92-2, miR-130a, miR-93, miR-16-1, miR-145, miR-17, miR-99b, miR-181b-1, miR-146, miR-181b-2, miR-16-2, miR-99a, miR-197, miR-10a, miR-224, miR-92-1, miR-27a, miR-221, miR-320, miR-7-1, miR-29b-2, miR-150, miR-30d, miR-29a, miR-23b, miR-135a-2, miR-223, miR-3p21-v, miR-128b, miR-30b, miR-29b-1, miR-106b, miR-132, miR-214, miR-7-3, miR-29c, miR-367, miR-30c-2, miR-27b, miR-140, miR-10b, miR-20, miR-129-1, miR-340, miR-30a, miR-30c-1, miR-106a, miR-32, miR-95, miR-222, miR-30e, miR-129-2, miR-345, miR-143, miR-182, miR-1-1, miR-133a-1, miR-200c, miR-194-1, miR-210, miR-181c, miR-192, miR-220, miR-213, miR-323, miR-375 and a combination thereof.

### Claim 61

A method of identifying an anti-pancreatic cancer agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in pancreatic cancer cells, wherein an increase in the level of the miR gene product in the cell, relative to a control cell, is indicative of the test agent being an anti-pancreatic cancer agent.

### Claim 62 (depends on 61)

The method of claim 61, wherein the miR gene product is selected from the group consisting of miR-326, miR-155, miR-339, miR-34c, miR-345, miR-152, miR-372, miR-128a and a combination thereof.

### Claim 63

A method of identifying an anti-pancreatic cancer agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in pancreatic cancer cells, wherein a decrease in the level of the miR gene product in the cell, relative to a control cell, is indicative of the test agent being an anti-pancreatic cancer agent.

### Claim 64 (depends on 63)

The method of claim 63, wherein the miR gene product is selected from the group consisting of miR-103-2, miR-107, miR-103-1, miR-342, miR-100, miR-24-2, miR-23a, miR-125a, miR-26a-1, miR-24-1, miR-191, miR-15a, miR-368, miR-26b, miR-125b-2, miR-125b-1, miR-26a-2, miR-335, miR-126, miR-1-2, miR-21, miR-25, miR-92-2, miR-130a, miR-93, miR-16-1, miR-145, miR-17, miR-99b, miR-181b-1, miR-146, miR-181b-2, miR-16-2, miR-99a, miR-197, miR-10a, miR-224, miR-92-1, miR-27a, miR-221, miR-320, miR-7-1, miR-29b-2, miR-150, miR-30d, miR-29a, miR-23b, miR-135a-2, miR-223, miR-3p21-v, miR-128b, miR-30b, miR-29b-1, miR-106b, miR-132, miR-214, miR-7-3, miR-29c, miR-367, miR-30c-2, miR-27b, miR-140, miR-10b, miR-20, miR-129-1, miR-340, miR-30a, miR-30c-1, miR-106a, miR-32, miR-95, miR-222, miR-30e, miR-129-2, miR-345, miR-143, miR-182, miR-1-1, miR-133a-1, miR-200c, miR-194-1, miR-210, miR-181c, miR-192, miR-220, miR-213, miR-323, miR-375 and a combination thereof.
